Non–gene-modified T cells for lymphoma
| NCT # (ACRONYM) . | Disease target . | Cell type . | Phase . | Sponsor . |
|---|---|---|---|---|
| NCT00002663 | Lymphoma, leukemia, other adult and pediatric solid tumors | Allogeneic EBV-specific CTLs | 1/2 | Memorial Sloan Kettering Cancer Center and National Cancer Institute |
| NCT01948180 | EBV-positive extranodal NK/T-cell lymphoma | Autologous EBV-specific CTLs (CMD-003) | 2 | Cell Medica Ltd |
| NCT00779337 | Lymphoma | Autologous AdE1- latent membrane–protein-specific CTLs | 1 | Queensland Institute of Medical Research, The Atlantic Philanthropies, Australian Department of Industry, Tourism and Resources, British Society for Haematology, National Health and Medical Research Council, Australia |
| NCT00005606 | Lymphoma, leukemia, multiple myeloma, plasma cell neoplasm | Allogeneic EBV-specific CTLs | 2 | Northwestern University, National Cancer Institute |
| NCT01636388 | HL | Allogeneic LMP-specific CTLs | 2 | New York Medical College, Children's Research Institute, Baylor College of Medicine, MD Anderson Cancer Center, City of Hope Medical Center, Johns Hopkins University, Ohio State University, University of Utah, University of Michigan |
| NCT01956084 | HL,HL, lymphoepithelioma; SCAEBV, leiomyosarcoma | Allogeneic LMP-1/2–specific CTLs | 1 | Children’s Research Institute |
| NCT02057445 | HL, NHL, LPD, | Allogeneic LMP-specific CTLs | 1 | New York Medical College, Children's Research Institute, Baylor College of Medicine, MD Anderson Cancer Center, University of Michigan, University of Utah, City of Hope Medical Center, Ohio University, Johns Hopkins University |
| NCT01498484 | NHL, EBV infection | Allogeneic EBV-specific CTLs | 2 | Atara Biotherapeutics, Memorial Sloan Kettering Cancer Center |
| NCT01447056 | HL, NHL, LPD, nasopharyngeal carcinoma, leiomyosarcoma, SCAEBV | Allogeneic LMP-specific CTLs | 1 | Baylor College of Medicine |
| NCT01555892 (GRALE) | HL, NHL, T/NK LPD, lymphoma | Autologous or syngeneic donor LMP-1/2–, EBNA-1–, and BARF-specific CTLs | 1 | Baylor College of Medicine, National Cancer Institute |
| NCT00062868 | HL, NHL, lymphoepithelioma, leiomyosarcoma | Autologous or allogeneic LMP-1/2–specific CTLs | 1 | Baylor College of Medicine |
| NCT02287311 (MABEL) | HL, NHL, SCAEBV, T/NK LPD | LMP-, BARF-1–, and EBNA-1– specific | 1 | Baylor College of Medicine |
| NCT01956084 | HL, NHL, SCAEBV, lymphoepithelioma, leiomyosarcoma | Allogeneic LMP 1/2 -specific CTLs | 1 | Children’s Research Institute |
| NCT00002663 | Lymphoma, leukemia, unspecified adult solid tumor, protocol specific, unspecified childhood solid tumor, protocol specific | Allogeneic EBV-specific CTLs | 1/2 | Atara Biotherapeutics, Memorial Sloan Kettering Cancer Center, National Cancer Institute |
| NCT02973113 (PREVALE) | HL, NHL, LPDs, EBV-related lymphoma, EBV-related PTLD, EBV-related NHL, EBV-related HL | Autologous EBV-specific CTLs + nivolumab (anti-PD-1 mAb) | 1 | Baylor College of Medicine |
| NCT01333046 (TACTAL) | HL, NHL | 5-azacitidine+ autologous NY-ESO-1, MAGEA4, PRAME, survivin-, and SSX-specific CTLs | 1 | Baylor College of Medicine, National Cancer Institute |
| NCT02203903 (RESOLVE) | Relapsed/refractory hematopoietic malignancies | Autologous or allogeneic WT1, NE, PR3, PRAME, MAGE-A3, MAGE-A4, NY-ESO, and survivin-specific CTLs | 1 | Children’s Research Institute, Johns Hopkins University |
| NCT02822495 | EBV-associated LPD, EBV lymphoma, EBV-related posttransplant LPD, EBV-associated viremia | Allogeneic EBV CTLs | Expanded access | Atara Biotherapeutics |
| NCT # (ACRONYM) . | Disease target . | Cell type . | Phase . | Sponsor . |
|---|---|---|---|---|
| NCT00002663 | Lymphoma, leukemia, other adult and pediatric solid tumors | Allogeneic EBV-specific CTLs | 1/2 | Memorial Sloan Kettering Cancer Center and National Cancer Institute |
| NCT01948180 | EBV-positive extranodal NK/T-cell lymphoma | Autologous EBV-specific CTLs (CMD-003) | 2 | Cell Medica Ltd |
| NCT00779337 | Lymphoma | Autologous AdE1- latent membrane–protein-specific CTLs | 1 | Queensland Institute of Medical Research, The Atlantic Philanthropies, Australian Department of Industry, Tourism and Resources, British Society for Haematology, National Health and Medical Research Council, Australia |
| NCT00005606 | Lymphoma, leukemia, multiple myeloma, plasma cell neoplasm | Allogeneic EBV-specific CTLs | 2 | Northwestern University, National Cancer Institute |
| NCT01636388 | HL | Allogeneic LMP-specific CTLs | 2 | New York Medical College, Children's Research Institute, Baylor College of Medicine, MD Anderson Cancer Center, City of Hope Medical Center, Johns Hopkins University, Ohio State University, University of Utah, University of Michigan |
| NCT01956084 | HL,HL, lymphoepithelioma; SCAEBV, leiomyosarcoma | Allogeneic LMP-1/2–specific CTLs | 1 | Children’s Research Institute |
| NCT02057445 | HL, NHL, LPD, | Allogeneic LMP-specific CTLs | 1 | New York Medical College, Children's Research Institute, Baylor College of Medicine, MD Anderson Cancer Center, University of Michigan, University of Utah, City of Hope Medical Center, Ohio University, Johns Hopkins University |
| NCT01498484 | NHL, EBV infection | Allogeneic EBV-specific CTLs | 2 | Atara Biotherapeutics, Memorial Sloan Kettering Cancer Center |
| NCT01447056 | HL, NHL, LPD, nasopharyngeal carcinoma, leiomyosarcoma, SCAEBV | Allogeneic LMP-specific CTLs | 1 | Baylor College of Medicine |
| NCT01555892 (GRALE) | HL, NHL, T/NK LPD, lymphoma | Autologous or syngeneic donor LMP-1/2–, EBNA-1–, and BARF-specific CTLs | 1 | Baylor College of Medicine, National Cancer Institute |
| NCT00062868 | HL, NHL, lymphoepithelioma, leiomyosarcoma | Autologous or allogeneic LMP-1/2–specific CTLs | 1 | Baylor College of Medicine |
| NCT02287311 (MABEL) | HL, NHL, SCAEBV, T/NK LPD | LMP-, BARF-1–, and EBNA-1– specific | 1 | Baylor College of Medicine |
| NCT01956084 | HL, NHL, SCAEBV, lymphoepithelioma, leiomyosarcoma | Allogeneic LMP 1/2 -specific CTLs | 1 | Children’s Research Institute |
| NCT00002663 | Lymphoma, leukemia, unspecified adult solid tumor, protocol specific, unspecified childhood solid tumor, protocol specific | Allogeneic EBV-specific CTLs | 1/2 | Atara Biotherapeutics, Memorial Sloan Kettering Cancer Center, National Cancer Institute |
| NCT02973113 (PREVALE) | HL, NHL, LPDs, EBV-related lymphoma, EBV-related PTLD, EBV-related NHL, EBV-related HL | Autologous EBV-specific CTLs + nivolumab (anti-PD-1 mAb) | 1 | Baylor College of Medicine |
| NCT01333046 (TACTAL) | HL, NHL | 5-azacitidine+ autologous NY-ESO-1, MAGEA4, PRAME, survivin-, and SSX-specific CTLs | 1 | Baylor College of Medicine, National Cancer Institute |
| NCT02203903 (RESOLVE) | Relapsed/refractory hematopoietic malignancies | Autologous or allogeneic WT1, NE, PR3, PRAME, MAGE-A3, MAGE-A4, NY-ESO, and survivin-specific CTLs | 1 | Children’s Research Institute, Johns Hopkins University |
| NCT02822495 | EBV-associated LPD, EBV lymphoma, EBV-related posttransplant LPD, EBV-associated viremia | Allogeneic EBV CTLs | Expanded access | Atara Biotherapeutics |
HD, Hodgkin disease; LPD, lymphoproliferative disorder/disease; SCAEBV, severe chronic active EBV infection syndrome.